Since 2017, lamivudine was progressively discontinued and replaced with tenofovir or entecavir. Chronic hepatitis B patients continued their antiviral treatment, except lamivudine and adefovir, which ...
OBJECTIVE: Despite the availability of treatment and vaccines for chronic hepatitis B infection, it remains a public health problem. The use of nucleos(t)ide antiviral agents is effective in ...
The hepatitis C virus usually spreads through blood. The most common way that people get it is from injecting drugs -- especially when they share needles or syringes. The risk of getting hepatitis ...
Antiviral Therapy: "Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: A review." BioMed Research International: "Effects and tolerance of silymarin (milk ...
The primary efficacy end point was hepatitis B surface antigen (HBsAg ... and were receiving NA monotherapy (entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate) for at least ...
Entecavir and tenofovir are the two most potent anti-HBV agents with the best resistance profile in nucleo(s)tide-naive patients with chronic hepatitis B. Tenofovir represents the optimal ...
Tenofovir alafenamide may be a top treatment option for chronic hepatitis B among patients with and without liver cirrhosis. Tenofovir alafenamide vs tenofovir disoproxil fumarate is associated with a ...